-
Blood: sutimlimab therapy improves severe hemolytic anemia in cold agglutinin disease
Time of Update: 2021-06-21
Bernd Jilma of the Medical University of Vienna, said: "The drug is well tolerated, resulting in a clinically significant increase in hemoglobin levels, and eliminating the need for blood transfusions, even for patients who have failed many previous treatments.
-
Results of the Phase II BEYOND study announced: Rotexip can improve the quality of life of adults with non-transfusion dependent (NTD) β-thalassemia
Time of Update: 2021-06-21
The purpose of this study is to evaluate the efficacy and safety of the world's first red blood cell maturation agent Rotexiper combined with the best supportive treatment for the treatment of adult non-transfusion dependent (NTD) β- thalassemia .
-
Leukemia: iFCG chemotherapy regimen for the treatment of chronic lymphocytic leukemia with IGHV mutation and without TP53 mutation
Time of Update: 2021-06-21
Response to treatmentResponse to treatmentAll in all, the results of the study revealed that only 3 cycles of iFCG chemotherapy is an effective time-limited treatment for CLL patients with IGHV mutations and no del(17p)/TP53 mutations .
-
Blood: The effect of glucocorticoids on the prognosis of patients with large B-cell lymphoma treated with CAR-T cell therapy
Time of Update: 2021-06-21
The higher cumulative dose of glucocorticoid after CAR-T cell infusion, long use time and early use are all related to a significant reduction in the overall survival of the patientIn conclusion, the results of this study indicate that when managing CAR-T cell therapy-related toxicity, the use of glucocorticoids should be controlled at the lowest dose and shortest duration as much as possible, and their activation time should be postponed as far as possible when clinically feasible.
-
JCO: Phase 3 TOURMALINE-MM1 trial of patients with relapsed/refractory MM who were treated with ixazomib-lenalidomide-dexamethasone in the final analysis of overall survival
Time of Update: 2021-06-21
A lower risk ratio was observed in a predetermined subgroup, suggesting that the ixazomib-Rd regimen has greater OS benefits compared to placebo-Rd : insensitive to any treatment (HR 0.
-
Nat Commun: Targeting PI3K/AKT overactivation induces cell death in chronic lymphocytic leukemia
Time of Update: 2021-06-21
In chronic lymphocytic leukemia (CLL), autonomous autoimmune reactive BCR (B cell receptor) signaling contributes to the survival of tumor cells , and currently established targeted therapy strategies mainly focus on inhibiting oncogenic kinases in the BCR pathway , By depriving the relevant signals, leading to cell death.
-
JCO: Final analysis results of Ixazomi combined with lenalidomide + dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM): Phase III clinical study TOURMALINE-MM1
Time of Update: 2021-06-21
The progression-free survival (PFS) benefit of Ixazomib-Rd in the treatment of relapsed or refractory multiple myeloma (RRMM) did not translate into the benefit of OS .
The progression-free survival (PFS) benefit of Ixazomib-Rd in the treatment of relapsed or refractory multiple myeloma (RRMM) did not translate into the benefit of OS .
-
Winbond Health Methylprednisolone Sodium Succinate for Injection passed the consistency evaluation of generic drugs
Time of Update: 2021-06-20
It has strong anti-inflammatory, anti-allergic, anti-shock, and immunosuppressive effects.
It is clinically used in the acute and critical phases of critically ill patients, as well as maintenance treatment after first aid .
-
Five companies voluntarily recalled illegal medical devices including intra-aortic balloon pump catheters
Time of Update: 2021-06-20
Road Venous/Arterial Blood Management Protection System (Registration Certificate Number: National Instruments Injection 20163662708), Disposable Pressure Transducer (Registration Certificate Number: National Instruments Injection 20163072744) were actively recalled .
Philips Medical Systems Nederland BV voluntarily recalled Magnetic Resonance Equipment (Registration Certificate No.
-
An article to answer the real difference between tumor and cancer
Time of Update: 2021-06-20
Carcinoma is the most common type of malignant tumor, formed by epithelial cells .
Transitional cell carcinoma is a type of cancer that forms in epithelial tissue called transitional epithelium, or urothelium .
People often use cancer to refer to malignant tumors, including carcinomas and sarcomas .
-
ASCO's blockbuster CAR-T therapy has a total remission rate of 80%, and Baiji Gene brings new AML clinical trial data
Time of Update: 2021-06-18
The researcher initiated the clinical study (IIT) co-lead investigator, Director Zhang Hui of Guangzhou Women’s and Children’s Medical Center, said: “We are very pleased to see that Baiji Gene Anti-CLL1CAR-T drug candidates show fast, efficient, Accurate and safe AML treatment effect, 10/11 patients responded positively to Anti-CLL1 CAR-T cell therapy within one month .
-
2021 ASCO express Zebutinib combined with PI3Kδ inhibitor Zandelisib for the treatment of relapsed/refractory B-cell malignancies
Time of Update: 2021-06-18
Research method This is a multi-cohort phase 1b study, which included patients with FL, CLL, MZL, MCL, DLBCL, or high-grade B-cell lymphoma (HGBCL), who had been treated for ≥1 times, bone marrow and organ function were good, and ECOG≤2 , And have not received PI3Ki or BTKi treatment in the past .
-
Liu Ruqian's team re-issued Natuer: Base editing technology is expected to treat sickle cell anemia in one go
Time of Update: 2021-06-18
Liu (Liu Ruqian) of the Broad Institute and other teams published a research paper titled "Base editing of haematopoietic stem cells rescues sickle cell disease in mice" in Nature online, which used a customized gland The purine base editor (ABE8e-NRCH) converts the SCD allele (HBBS) to Makassar β-globin (HBBG), which is a non-pathogenic variant .
-
["Only" has come] Optimize the AML diagnosis and treatment model, and explore the application of Vinekal in China
Time of Update: 2021-06-18
Many hematology experts and scholars use the Internet as a department to talk about the frontiers of AML Chinese and foreign theories, think about the changes in the diagnosis and treatment of the era, and share "practical" experience to optimize the clinical application of Venecla in China, hoping that more standardized clinical management can help China AML patients bring more benefits .
-
2021 EHA blockbuster Naratuximab emtansine + rituximab in the treatment of DLBCL and other B-NHL safety and efficacy exploration
Time of Update: 2021-06-18
Professor Moshe Yair Levy from the United States and others conducted a phase 2 study to evaluate the safety of nara+RTX in the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and other B-NHL patients Sex and efficacy .
-
2021 ASCO fixed course of Ibrutinib combined with Venecla regimen achieves considerable efficacy in CLL
Time of Update: 2021-06-18
Research methods: The study included newly-treated CLL/small lymphocytic lymphoma (SLL) patients ≤70 years of age who received 3 cycles of Ibrutinib monotherapy, followed by 12 cycles of I+V regimen treatment (Ibutin Ni: 420 mg orally per day; Venecla: increasing the dose to 400 mg per day) .
-
The final analysis of the TOURMALINE-MM1 research is released, come and watch!
Time of Update: 2021-06-18
The final analysis of the TOURMALINE-MM1 study showed that, due to the influence of subsequent treatment, although the OS benefit of IRd compared with pRd in the ITT population was not statistically significant, it was in subgroups with poor prognostic factors (including high-risk cytogenetic abnormalities).
-
[A quick look at ASCO's big coffee] Professor Xiao Zhijian: Bellinto Oumab combined with the third-generation TKI, the new Chemo-free solution is expected to replace transplantation!
Time of Update: 2021-06-18
A phase II study: early data of CD19-CD3 bispecific BiTE immunotherapy belintouximab combined with third-generation TKI Ponatinib in the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients .
-
Professor Qian Wenbin: The latest development of CAR-T therapy for B-cell lymphoma [A series of activities of the Lymphocytic Disease Group of the Hematology Branch of the Chinese Medical Association]
Time of Update: 2021-06-18
Summary Professor Qian Wenbin concluded: CAR-T therapy has achieved good results in B-cell lymphoma, but currently about 50% of patients still cannot benefit from CAR-T therapy, and about 20% of patients Disease progression after obtaining CR .
-
2021 EHA first reports Zebutinib + Lenalidomide + R-CHOP in the treatment of DLBCL
Time of Update: 2021-06-18
Although the PHOENIX5 study did not achieve the primary endpoint of the benefit of event-free survival (EFS), in patients <60 years old, Ibritinib combined with R-CHOP treatment of non-GCB DLBCL EFS, progression-free survival (PFS) and Compared with R-CHOP, OS has been improved .
Therefore, in this study, the combination of Zebutinib+lenalidomide+R-CHOP was used to treat medium- to high-risk DLBCL.
